Clinical Trial

Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA)

Study acronym: HCCAA
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study aims to measure safety, tolerability and biomarker-based efficacy of NPI-001 (AT-001) in Subjects with Hereditary Cystatin C Amyloid Angiopathy (HCCAA). In the study participants receive increasing dose or active treatment (250 mg vs 500mg vs 750 mg) or matched placebo in the form of tablets BID.
Trial Details
NCT Number NCT07716865
Lead Sponsor Arctic Therapeutics
Conditions Hereditary Cystatin C Amyloid Angiopathy (HCCAA), Hemorrhage Brain, Hemorrhage Cerebral
Enrollment 15 participants
Start Date 2024-04-03
Primary Completion 2026-12-29 (estimated)
Study Completion 2027-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-21